|
11.09.2024 22:27:14
|
Guidance for the 2024/25 financial year
ANNOUNCEMENT NO. 272
11 September 2024
Guidance for the 2024/25 financial year
ChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information.
For 2024/25, ChemoMetec expects revenue in the range of DKK 435-450 million (2023/24: DKK 407.4 million) and EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2 million).
The annual report for 2023/24, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2024/25 (p. 40).
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ChemoMetec A-Smehr Nachrichten
|
22.10.24 |
Closing of acquisition of Ovizio Imaging Systems SA (GlobeNewswire) | |
|
16.10.24 |
Acquisition of Ovizio Imaging Systems SA (GlobeNewswire) | |
|
16.10.24 |
Upgrade of revenue and operating profit guidance (GlobeNewswire) | |
|
11.10.24 |
ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA (GlobeNewswire) |
Analysen zu ChemoMetec A-Smehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.